Wednesday, July 8, 2026

biotech · Lupus Nephritis · Primary or Secondary Progressive Multiple Sclerosis · KYTX

Kyverna Therapeutics

Kyverna Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

5980 Horton St, Suite 550, Emeryville, California 94608, US HQ
2018 Founded
155 Employees
Public company Type
KYTX · NYSE Ticker
Company details
Status
Public
HQ
5980 Horton St, Suite 550, Emeryville, California 94608, US
Founded
2018
Employees
155
Programs
14
Drugs
31
Patents
2
Intelligence · Clinical Programs

Kyverna Therapeutics projects

3 ClinicalTrials.gov programs sponsored by Kyverna Therapeutics.

Kyverna Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. KYV-101

    Kyverna Therapeutics

    Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome

    phase 3 small molecule active

    1 trial
  2. KYV101-006

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial
  3. Standard of Care Treatment

    Kyverna Therapeutics

    Myasthenia Gravis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Kyverna Therapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.